Improved prognosis of low baseline neutrophil‑to‑lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes

  • Authors:
    • Yukie Fujimoto
    • Hiromi Ozawa
    • Tomoko Higuchi
    • Yoshimasa Miyagawa
    • Ayako Bun
    • Michiko Imamura
    • Yasuo Miyoshi
  • View Affiliations

  • Published online on: December 4, 2018     https://doi.org/10.3892/mco.2018.1783
  • Pages: 275-284
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Although the neutrophil‑to‑lymphocyte ratio (NLR) is a valuable prognostic factor for early breast cancer, the patient subgroups that may benefit the most from NLR analysis remain unknown. The present study analyzed the prognostic significance of NLR according to absolute lymphocyte counts (ALCs). A total of 889 patients with operated early breast cancers were retrospectively recruited. Existing NLR and ALC baseline data from the time‑period prior to operation or preoperative chemotherapy were collected. The cut-off value for NLR was set at 2.72 according to the receiver operating characteristic curve. Recurrence‑free survival (RFS) of NLR‑low patients at baseline (n=582) was significantly better than that of NLR‑high patients (n=307, P=0.036). Improved patient prognoses were observed in the NLR‑low, ALC‑high (>1,688/µl; 5‑year RFS, 0.88 vs. 0.57; P<0.0001) subgroup (n=355), but not in the NLR‑low, ALC‑low (≤1,688/µl; 5‑year RFS, 0.87 vs. 0.87; P=0.46) subgroup (n=534). Using multivariate analysis, NLR was observed to be a significant and independent factor for RFS (hazard ratio: 3.52; 95% confidence interval: 1.61‑7.32; P=0.0023) in the ALC‑high breast cancer subgroup. Prognostic significance for baseline NLR was found exclusively in the ALC ‑ high subgroup. Since NLR is a simple marker, the results obtained here might be useful for identifying patients who have high recurrence risk, and those that are candidates for additional treatments.
View Figures
View References

Related Articles

Journal Cover

February-2019
Volume 10 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fujimoto Y, Ozawa H, Higuchi T, Miyagawa Y, Bun A, Imamura M and Miyoshi Y: Improved prognosis of low baseline neutrophil‑to‑lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes. Mol Clin Oncol 10: 275-284, 2019
APA
Fujimoto, Y., Ozawa, H., Higuchi, T., Miyagawa, Y., Bun, A., Imamura, M., & Miyoshi, Y. (2019). Improved prognosis of low baseline neutrophil‑to‑lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes. Molecular and Clinical Oncology, 10, 275-284. https://doi.org/10.3892/mco.2018.1783
MLA
Fujimoto, Y., Ozawa, H., Higuchi, T., Miyagawa, Y., Bun, A., Imamura, M., Miyoshi, Y."Improved prognosis of low baseline neutrophil‑to‑lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes". Molecular and Clinical Oncology 10.2 (2019): 275-284.
Chicago
Fujimoto, Y., Ozawa, H., Higuchi, T., Miyagawa, Y., Bun, A., Imamura, M., Miyoshi, Y."Improved prognosis of low baseline neutrophil‑to‑lymphocyte ratio is significantly exclusive in breast cancer patients with high absolute counts of lymphocytes". Molecular and Clinical Oncology 10, no. 2 (2019): 275-284. https://doi.org/10.3892/mco.2018.1783